Clinical trial
ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid…
NCT00132158 · St. Jude Children's Research Hospital, Other · Completed
Key facts
| NCT number | NCT00132158 |
|---|---|
| Title | ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors |
| Official title | A Dose Finding Study (Phase I) of the Combination of ZD1839 (Iressa®) and an Oral Formulation of Irinotecan (Camptosar™) in Children With Refractory Solid Tumors |
| Lead sponsor | St. Jude Children's Research Hospital, Other |
| Collaborators | AstraZeneca Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Glioblastoma, Rhabdomyosarcomas, Neuroblastoma, Osteosarcoma |
| Intervention type | Drug |
| Interventions | Irinotecan (Camptosar), Gefitinib (Iressa) |
| Enrollment | 19 |
| Start date | Sep 1, 2005 |
| Primary completion | Oct 1, 2011 |
| Completion | Oct 1, 2011 |
| First posted | Aug 19, 2005 |
| Last update posted | Apr 17, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: